Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning a€“ Interim Results From a Phase II Clinical Trial »
02/23/14

A Systematic Search Into The Role Of IGHV Gene Replacement In Shaping The Immunoglobulin Repertoire Of Chronic Lymphocytic Leukemia »
02/23/14

Modulation of B Cell Receptor Signalling By IL-4 In Chronic Lymphocytic Leukaemia »
02/23/14

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia a€“ First Results Of a Randomized German-French Cooperative Phase III Trial »
02/23/14

Target Engagement, Pathway Inhibition, and Efficacy Of The Brutona€™s Tyrosine Kinase (Btk) Inhibitor CC-292 »
02/23/14

Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199 »
02/23/14

Backtracking Subclonal Mutations Of TP53 In Myelodysplasia (MDS) With Del(5q) With Next-Generation Sequencing (NGS) »
02/23/14

Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay »
02/23/14

IGHV Mutation Status Does Not Add Prognostic Information In The Background Of Mutations In TP53 and SF3B1, and Deletions Of 17p and 11q, Which Are Independent Adverse Prognostic Parameters In CLL »
02/23/14

Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study »
02/23/14